HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

An important goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that elicit effective antiviral humoral immunity. One novel approach comprises priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on virus-like particles....

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xiaoying, Basu, Rahul, Sawant, Sheetal, Beaumont, David, Kwa, Sue Fen, LaBranche, Celia, Seaton, Kelly E., Yates, Nicole L., Montefiori, David C., Ferrari, Guido, Wyatt, Linda S., Moss, Bernard, Alam, S. Munir, Haynes, Barton F., Tomaras, Georgia D., Robinson, Harriet L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709589/
https://www.ncbi.nlm.nih.gov/pubmed/29021394
http://dx.doi.org/10.1128/JVI.01077-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709589/
https://www.ncbi.nlm.nih.gov/pubmed/29021394
http://dx.doi.org/10.1128/JVI.01077-17

Ejemplares similares